ReviewAntibiotics (Basel, Switzerland)2025
Difficult-to-Treat
Review in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Enumeration Method forMicroorganisms · 2026Article
- Detection of carbapenem resistance mechanisms in difficult-to-treat Pseudomonas aeruginosa clinical isolates from a tertiary care hospital in Egypt.BMC microbiology · 2026Article
- A Ten-Year Trend of Antimicrobial Resistance inOpen forum infectious diseases · 2026Article
- Integrative Systems-Level Transcriptomic Network Analysis Identifies Candidate Genes Associated with Biofilm Formation and Virulence inInternational journal of molecular sciences · 2026Article
- Tackling Biofilm-Forming Pathogens: A Challenge to Overcome in the Fight Against Infectious Diseases.Pathogens (Basel, Switzerland) · 2026Review
- The Silent Threat: Unveiling Pathogenicity and Antimicrobial Resistance in Nonfermenting Gram-Negative Bacilli.Cureus · 2026Review
- Case report: rapid in vivo resistance mechanism shifts in multiple carbapenem-resistant Pseudomonas aeruginosa strains after esophagectomy in an immunocompromised patient: a case report.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Integrated Phenotypic, Proteomic (MALDI-TOF MS), and Genomic (WGS) Investigation of a Prolonged Hospital Outbreak ofAntibiotics (Basel, Switzerland) · 2026Article
- Carbapenem-resistant Gram-negative pathogens: molecular epidemiology, diagnostic advances, and emerging therapeutic strategies.Frontiers in microbiology · 2026Review
- Duration Matters: Tailoring Antibiotic Therapy for Ventilator-Associated Pneumonia.Antibiotics (Basel, Switzerland) · 2026Review
- Early CytoSorb Hemoadsorption in a Neutropenic Acute Myeloid Leukemia Patient with Carbapenem-ResistantDiseases (Basel, Switzerland) · 2025Article
- The Paradox of Healthcare in the 'Superbugs' Era: Current Challenges and Future Directions.Pathogens (Basel, Switzerland) · 2025Review
- Clinical Characteristics, Microbiological Profile, and Mortality Predictors in Pediatric Community-Acquired Sepsis: A Single-Center Study.Turkish archives of pediatrics · 2025Article
- Antimicrobial Resistance and Therapy in the Intensive Care Unit.Antibiotics (Basel, Switzerland) · 2025Article
- Incidence and risk factors of resistant Pseudomonas aeruginosa infections: a multicenter study in Lebanese tertiary hospitals.BMC infectious diseases · 2025Observational
- In vitro and in vivo investigation of the antibacterial, antivirulence, and antiquorum sensing activities of β-carotene against difficult-to-treat resistant Pseudomonas aeruginosa.BMC microbiology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of infections caused by difficult-to-treat
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.